The efficacy of sapacitabine in treating patients with acute myeloid leukemia.
Czemerska M, Robak T, Wierzbowska A.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2018.1524875 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för sapacitabine. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
14 träffarTDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.
Mol Cancer Ther · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-17-0110Sapacitabine in the treatment of acute myeloid leukemia.
Norkin M, Richards AI.
Expert Rev Anticancer Ther · journal article · DOI 10.1586/14737140.2015.1102064A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.
Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D.
Leukemia · comparative study; randomized controlled trial; journal article · DOI 10.1038/leu.2015.38Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.
Lim MY, Jamieson K.
Clin Interv Aging · review-article; review; journal article · DOI 10.2147/cia.s39558Improvement of the antitumor activity of poorly soluble sapacitabine (CS-682) by using Soluplus® as a surfactant.
Obata T, Suzuki Y, Ogawa N, Kurimoto I, Yamamoto H, Furuno T, Sasaki T, Tanaka M.
Biol Pharm Bull · research support, non-u.s. gov't; journal article · DOI 10.1248/bpb.b13-00898Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W.
Lancet Oncol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(12)70436-9Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ, Nowak B, Wang YQ, Plunkett W.
Chin J Cancer · research-article; journal article; research support, n.i.h., extramural · DOI 10.5732/cjc.012.10077Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F, Diaz I, Peters GJ.
Expert Opin Investig Drugs · editorial · DOI 10.1517/13543784.2012.666236Sapacitabine for cancer.
Liu X, Kantarjian H, Plunkett W.
Expert Opin Investig Drugs · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1517/13543784.2012.660249Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M, Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J, Faivre S, Cvitkovic E, Le Tourneau C, Calvo F, Raymond E.
Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjc.6603896A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
Gilbert J, Carducci MA, Baker SD, Dees EC, Donehower R.
Invest New Drugs · clinical trial, phase i; journal article · DOI 10.1007/s10637-006-8219-0A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.
Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-006-5392-0Isolation of deoxycytidine kinase from Ehrlich carcinoma cells by affinity chromatography based on a substrate analog, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-N4-palmitoylcytosine++ +.
Uchida H, Chen YX, Morinaga H, Hayashi Y, Matsuda A, Obata T, Endo Y, Sasaki T.
Biol Pharm Bull · research support, non-u.s. gov't; journal article · DOI 10.1248/bpb.22.83